Capital Group Private Client Services Inc. Acquires 1,222 Shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)

Capital Group Private Client Services Inc. raised its holdings in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVNGet Rating) by 1.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 68,561 shares of the company’s stock after acquiring an additional 1,222 shares during the period. Capital Group Private Client Services Inc.’s holdings in Biohaven Pharmaceutical were worth $8,129,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Thrivent Financial for Lutherans acquired a new stake in shares of Biohaven Pharmaceutical during the fourth quarter valued at about $93,941,000. American Century Companies Inc. boosted its stake in shares of Biohaven Pharmaceutical by 259.4% during the first quarter. American Century Companies Inc. now owns 684,834 shares of the company’s stock valued at $81,201,000 after purchasing an additional 494,275 shares in the last quarter. Eversept Partners LP acquired a new position in shares of Biohaven Pharmaceutical in the fourth quarter worth approximately $43,428,000. Eventide Asset Management LLC lifted its stake in shares of Biohaven Pharmaceutical by 23.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,635,000 shares of the company’s stock worth $225,319,000 after acquiring an additional 310,000 shares during the period. Finally, GW&K Investment Management LLC lifted its stake in shares of Biohaven Pharmaceutical by 389.3% in the fourth quarter. GW&K Investment Management LLC now owns 380,437 shares of the company’s stock worth $52,428,000 after acquiring an additional 302,679 shares during the period. Institutional investors own 78.19% of the company’s stock.

Insider Activity

In other news, Director Gregory Bailey acquired 38,000 shares of the firm’s stock in a transaction dated Friday, August 19th. The stock was purchased at an average price of $148.04 per share, for a total transaction of $5,625,520.00. Following the completion of the acquisition, the director now directly owns 2,583,658 shares in the company, valued at approximately $382,484,730.32. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 12.40% of the company’s stock.

Analyst Upgrades and Downgrades

BHVN has been the topic of a number of recent analyst reports. Wedbush lowered Biohaven Pharmaceutical from an “outperform” rating to a “neutral” rating and set a $148.50 price objective on the stock. in a research note on Monday, August 8th. Piper Sandler lowered Biohaven Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $149.00 price target on the stock. in a research note on Thursday, August 18th. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $157.17.

Biohaven Pharmaceutical Stock Down 0.1 %

NYSE BHVN opened at $150.71 on Friday. The company has a market cap of $10.78 billion, a price-to-earnings ratio of -10.17 and a beta of 1.04. Biohaven Pharmaceutical Holding Company Ltd. has a 52 week low of $79.01 and a 52 week high of $151.51. The business has a 50 day moving average price of $147.28 and a 200-day moving average price of $133.16.

Biohaven Pharmaceutical (NYSE:BHVNGet Rating) last released its quarterly earnings data on Friday, August 5th. The company reported ($6.21) EPS for the quarter, missing the consensus estimate of ($2.79) by ($3.42). The firm had revenue of $215.08 million during the quarter, compared to analysts’ expectations of $209.33 million. On average, equities research analysts anticipate that Biohaven Pharmaceutical Holding Company Ltd. will post -13.29 earnings per share for the current year.

About Biohaven Pharmaceutical

(Get Rating)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

Featured Stories

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVNGet Rating).

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.